Mesothelioma.com Resources for Patients and their Families

Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study

Brief Summary

This study will provide continuing availability to tazemetostat as a single agent to subjects who have completed their participation in an antecedent tazemetostat study (either with monotherapy or combination therapy). In addition, long-term safety and overall survival will be collected.

Tracking Information
First Received DateAugust 5, 2016
Last Changed DateSeptember 13, 2016
Start DateAugust 2016
Anticipated Primary Completion DateDecember 2023
Primary Outcome Measures

Long-term safety profile of tazemetostat measured by number of AEs and duration of exposure to tazemetostat [Time Frame: From the date of first dose to discontinuation for any reason, including disease progression, withdrawal of consent or death, up to 7 years]

Secondary Outcome Measures

The overall survival (OS) [Time Frame: From the date of the first dose of tazemetostat to the date of death due to any cause, up to 7 years]

Descriptive Information
PhasePhase 2
Study TypeInterventional
Condition
  • Diffuse Large B-cell Lymphoma
  • Follicular Lymphoma
  • Malignant Rhabdoid Tumors (MRT)
  • Rhabdoid Tumors of the Kidney (RTK)
  • Atypical Teratoid Rhabdoid Tumors (ATRT)
  • Synovial Sarcoma
  • Epitheliod Sarcoma
  • Mesothelioma
  • Advanced Solid Tumors
Intervention
  • Drug: Tazemetostat
Study Arms / Comparison Groups1 / 0
Recruitment Information
Recruitment StatusRecruiting
Anticipated Enrollment300
GenderAll
Ages18 Years - N/A
Accepts Healthy VolunteersNo
Contact Harry Miao, MD, PhD
Email: clinicaltrials@epizyme.com
Phone: 855-500-1011
Eligibility Criteria

Inclusion Criteria:

1. Has demonstrated clinical benefit from treatment with tazemetostat.

2. Is currently receiving tazemetostat as either monotherapy or in combination with other approved drug(s) or investigational agent(s) on an Epizyme-sponsored clinical trial or any other clinical trial being conducted with tazemetostat that is not sponsored by Epizyme (including but not limited to, Investigator initiated trials). For subjects on combination therapy, the other therapeutic(s) must have been completed or will be provided by a source other than Epizyme

3. Has provided signed written informed consent

4. Has a life expectancy of >3 months

5. Has adequate hematopoietic, coagulation, renal and hepatic function. Subject must remain eligible for continued treatment with tazemetostat according to the eligibility and treatment criteria from the antecedent study.

6. For French subjects only: Is either affiliated with or a beneficiary of a social security category.

7. Female subjects of childbearing potential must:

- Have a negative beta-human chorionic gonadotropin (β-hCG) pregnancy test at time of study entry and within 14 days prior to planned first dose of investigational product, and

- Agree to use effective contraception until 30 days following the last dose of investigational product and have a male partner who uses a condom or

- Practice true abstinence or

- Have a male partner who is vasectomized.

8. Male subjects with a female partner of childbearing potential must:

- Be vasectomized, or

- Agree to use condoms until 30 days following the last dose of investigational product, or

- Have a female partner who is NOT of childbearing potential.

Exclusion Criteria:

1. Has had an interruption of tazemetostat dosing of >14 days from the antecedent clinical study to starting the rollover study.

2. Has any other malignancy other than the one for which they are receiving tazemetostat Exception: Subject who has been disease-free of a prior malignancy for 5 years, or subject with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma is eligible.

3. Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from time of enrollment to while on study.

4. Is currently taking any prohibited medication(s).

5. Is unable to take oral medications, malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea or vomiting) that might impair the bioavailability of tazemetostat

6. Has an uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, or psychiatric illness/social situations that would limit compliance with study requirements.

7. For female subjects of childbearing potential: Is pregnant or nursing

8. Has been permanently discontinued from tazemetostat therapy due to adverse event, intolerance or treatment failure

Administrative Information
NCTIDNCT02875548
Responsible Party,
SponsorEpizyme, Inc.
Verification DateSeptember 2016
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog

FEATURED CONTENT:


RECENT POSTS:

The Growing Global Asbestos Trade

Catching the Criminals: Mesothelioma Victim Frank Bender’s Legacy

Scientists Discover Possible Genetic Link for Mesothelioma in Young Adults

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: